长森药业成立于2012年，是由全球知名化学药物研发专家领衔的创新药研发公司。公司凝聚了一批在新药研发颇有成就的研发带头人和年轻有为的药物化学科学家，本着“创新、卓越”的宗旨，致力于自主研发国际领先的，拥有全球知识产权的创新药产品，满足临床未竟需求。公司聚焦抗病毒、肿瘤免疫、自身免疫疾病等领域的原研药开发与产业化，以免疫学机理和临床转化为基础，构建并发挥自主研发体系优势，凭借丰富的临床洞察与成果转化能力，开展满足概念验证（Proof of Concept）热门靶点的创新药开发。

自成立以来，长森药业已开展多个自主研发的小分子创新药项目（FIC，first in class），多个产品进入临床试验阶段，其中两项临床研究已进入临床2期研究阶段。核心产品临床评估指标达到国际领先水平，有希望成为相关领域的重大突破（BIC，best in class）。预计未来三到五年，更多自主研发项目进入后期临床研究的同时，公司也将迈入产业化和商业化的高速发展阶段。 

公司总部位于闵行莘庄工业园，建有近4000m2的创新药研发实验室及转化中心。公司是国家高新技术企业，上海市“专精特新”中小企业，拥有授权发明专利40余项。

Founded in 2012, Longwood Biopharma is an innovative drug discovery company led by world-renowned experts in chemical drug discovery and development. With a team of accomplished R&D experts and young talented medicinal chemistry professionals, the company is dedicated to the independent research and development of world-class innovative drug products with global intellectual property rights to fulfill the unmet clinical needs. The company focuses on the development and industrialization of innovative drugs in the fields of anti-virus, tumor immunity and autoimmune diseases, leveraging the advantages of our well-built R&D system. Based on our rich clinical insights and results translation capabilities, we are developing innovative drugs for the hot targets with proof-of-concept.

Since its establishment, Longwood Biopharma has carried out several self-developed small molecule innovative drug projects (FIC, first in class), which several products in clinical trials, two of them in clinical study phase 2. With world-class performance in clinical evaluation, our core product are expected to become major breakthroughs in related fields (BIC, best in class). It is expected that in the next three to five years, more self-developed projects will enter late-stage clinical studies while the company will move into a high-speed development stage of industrialization and commercialization. 

Headquartered in Xinzhuang Industrial Park, Minhang District, Shanghai, the company has an innovative drug R&D center of nearly 4,000m². The company has qualified as National High-Tech Enterprise, Shanghai Specialized&Sophisticated SME, and has over 40 authorized invention patents.